First Tracks Biotherapeutics Inc

First Tracks Biotherapeutics insiders buy big RSU/ESO awards—showing confidence amid a 25% dip, hinting at a buying window as the stock nears its 52‑week low.

EcoR1 Capital’s first‑day buy‑in of First Tracks shares signals strong confidence and may stabilize its stock, boosting investor interest and long‑term growth prospects.

Insider buying surges at First Tracks Biotherapeutics (TRAX) post‑spin‑off, with executives locking in 150k+ options and RSUs, signaling confidence and potential dilution as the company looks to hit key milestones.